167 related articles for article (PubMed ID: 30009879)
21. A simplified prognostic index for chronic lymphocytic leukemia treated with ibrutinib: Results from a multicenter retrospective cohort study.
Gordon MJ; Sitlinger A; Salous T; Alqahtani H; Churnetski M; Rivera X; Wisniewski P; Cohen J; Patel K; Shadman M; Choi M; Hill B; Stephens D; Persky D; Brander D; Danilov AV
Leuk Res; 2020 Feb; 89():106302. PubMed ID: 31982152
[No Abstract] [Full Text] [Related]
22. Chronic lymphocytic leukemia, autoimmune hemolytic anemia and ibrutinib: a case report and review of the literature.
Molica S; Levato L; Mirabelli R
Leuk Lymphoma; 2016; 57(3):735-7. PubMed ID: 26337717
[No Abstract] [Full Text] [Related]
23. The clinical safety of ibrutinib in chronic lymphocytic leukemia.
Molica S
Expert Opin Drug Saf; 2015 Oct; 14(10):1621-9. PubMed ID: 26359217
[TBL] [Abstract][Full Text] [Related]
24. Ibrutinib: searching for a partner drug.
Kater AP; Brown JR
Lancet Oncol; 2019 Jan; 20(1):3-5. PubMed ID: 30522966
[No Abstract] [Full Text] [Related]
25. ALPINE: zanubrutinib versus ibrutinib in relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma.
Hillmen P; Brown JR; Eichhorst BF; Lamanna N; O'Brien SM; Qiu L; Salmi T; Hilger J; Wu K; Cohen A; Huang J; Tam CS
Future Oncol; 2020 Apr; 16(10):517-523. PubMed ID: 32207333
[TBL] [Abstract][Full Text] [Related]
26. Ibrutinib-associated hemophagocytic lymphohistiocytosis: A case series from Johns Hopkins.
Ambinder AJ; Hambley B; Shanbhag S; Merrill SA
Am J Hematol; 2019 Nov; 94(11):E296-E299. PubMed ID: 31400009
[No Abstract] [Full Text] [Related]
27. Survival adjusting for crossover: phase 3 study of ibrutinib
Coutre S; Tedeschi A; Robak T; Barr PM; Owen C; Bairey O; Burger J; Zhou C; Styles L; James DF; Kipps TJ
Haematologica; 2018 Jun; 103(6):e249-e251. PubMed ID: 29170253
[No Abstract] [Full Text] [Related]
28. Rapid onset of hemophagocytic lymphohistiocytosis in a patient with refractory chronic lymphocytic leukemia treated with ibrutinib.
Poole A; Girard N; Clayton F; Tantravahi SK
Leuk Lymphoma; 2017 May; 58(5):1258-1261. PubMed ID: 27750463
[No Abstract] [Full Text] [Related]
29. HBV reactivation in CLL patients with occult HBV infection treated with ibrutinib without viral prophylaxis.
Innocenti I; Morelli F; Autore F; Corbingi A; Pasquale R; Sorà F; Pompili M; Laurenti L
Leuk Lymphoma; 2019 May; 60(5):1340-1342. PubMed ID: 30730231
[No Abstract] [Full Text] [Related]
30. Long-term Efficacy of Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia: Results of the Polish Adult Leukemia Study Group Observational Study.
Pula B; Iskierka-Jazdzewska E; Dlugosz-Danecka M; Szymczyk A; Hus M; Szeremet A; Drozd-Sokolowska J; Waszczuk-Gajda A; Zaucha JM; Holojda J; Piszczek W; Steckiewicz P; Wojciechowska M; Osowiecki M; Knopinska-Posluszny W; Dudzinski M; Zawirska D; Subocz E; Halka J; Pluta A; Wichary R; Kumiega B; Budziszewska BK; Jurczak W; Lech-Maranda E; Giannopoulos K; Robak T; Jamroziak K
Anticancer Res; 2020 Jul; 40(7):4059-4066. PubMed ID: 32620653
[TBL] [Abstract][Full Text] [Related]
31. Psoriasis: a new adverse event of ibrutinib.
Rapparini L; Massi A; Baraldi C; Gugliotta G; Pileri A
Ital J Dermatol Venerol; 2024 Apr; 159(2):205-207. PubMed ID: 38287741
[No Abstract] [Full Text] [Related]
32. Is HBV prophylaxis required during CLL treatment with ibrutinib?
Tedeschi A; Frustaci AM; Mazzucchelli M; Cairoli R; Montillo M
Leuk Lymphoma; 2017 Dec; 58(12):2966-2968. PubMed ID: 28535112
[No Abstract] [Full Text] [Related]
33. Spuriously low lymphocyte count associated with pseudoerythroblastemia in a patient with chronic lymphocytic leukemia treated with ibrutinib.
Robier C; Beham-Schmid C; Neubauer M
Clin Chem Lab Med; 2018 Apr; 56(5):e112-e114. PubMed ID: 29252190
[No Abstract] [Full Text] [Related]
34. [Chronic Lymphocytic Leukemia. New targeted therapy option Ibrutinib].
Bruhn C
Med Monatsschr Pharm; 2014 Jul; 37(7):268-9. PubMed ID: 25065170
[No Abstract] [Full Text] [Related]
35. Pharmacovigilance during ibrutinib therapy for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) in routine clinical practice.
Finnes HD; Chaffee KG; Call TG; Ding W; Kenderian SS; Bowen DA; Conte M; McCullough KB; Merten JA; Bartoo GT; Smith MD; Leis J; Chanan-Khan A; Schwager SM; Slager SL; Kay NE; Shanafelt TD; Parikh SA
Leuk Lymphoma; 2017 Jun; 58(6):1376-1383. PubMed ID: 27820970
[TBL] [Abstract][Full Text] [Related]
36. The effectiveness of ibrutinib in chronic lymphocytic leukaemia: a nationwide, population-based study in the Netherlands.
van der Straten L; Levin MD; Visser O; Blijlevens NMA; Cornelissen JJ; Doorduijn JK; Kater AP; Dinmohamed AG
Br J Haematol; 2020 Mar; 188(6):e109-e112. PubMed ID: 31991479
[No Abstract] [Full Text] [Related]
37. Miliary tuberculosis after initiation of ibrutinib in chronic lymphocytic leukemia.
Wang SY; Ebert T; Jaekel N; Schubert S; Niederwieser D; Al-Ali HK
Ann Hematol; 2015 Aug; 94(8):1419-20. PubMed ID: 25903044
[No Abstract] [Full Text] [Related]
38. Ibrutinib in very elderly patients with relapsed/refractory chronic lymphocytic leukemia: A real-world experience of 71 patients treated in France: A study from the French Innovative Leukemia Organization (FILO) group.
Michallet AS; Campidelli A; Lequeu H; Dilhuydy MS; Tournilhac O; Fornecker LM; Dupuis J; Cymbalista F; De Guibert S; Delmer A; Vilque JP; Ghez D; Leblond V; Subtil F; Feugier P; Ysebaert L
Am J Hematol; 2017 Jun; 92(6):E105-E107. PubMed ID: 28295510
[No Abstract] [Full Text] [Related]
39. Ibrutinib Therapy Increases T Cell Repertoire Diversity in Patients with Chronic Lymphocytic Leukemia.
Yin Q; Sivina M; Robins H; Yusko E; Vignali M; O'Brien S; Keating MJ; Ferrajoli A; Estrov Z; Jain N; Wierda WG; Burger JA
J Immunol; 2017 Feb; 198(4):1740-1747. PubMed ID: 28077600
[TBL] [Abstract][Full Text] [Related]
40. Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial.
Moreno C; Greil R; Demirkan F; Tedeschi A; Anz B; Larratt L; Simkovic M; Samoilova O; Novak J; Ben-Yehuda D; Strugov V; Gill D; Gribben JG; Hsu E; Lih CJ; Zhou C; Clow F; James DF; Styles L; Flinn IW
Lancet Oncol; 2019 Jan; 20(1):43-56. PubMed ID: 30522969
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
